Literature DB >> 29768155

Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.

Lee Ratner1, Thomas A Waldmann2, Murali Janakiram3, Jonathan E Brammer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29768155     DOI： 10.1056/NEJMc1803181

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  68 in total

Review 1.  Challenges and implications of genomics for T-cell lymphomas.

Authors:  Eric D Jacobsen; David M Weinstock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Strategies for Predicting Response to Checkpoint Inhibitors.

Authors:  Roberta Zappasodi; Jedd D Wolchok; Taha Merghoub
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 3.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

4.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Authors:  Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim
Journal:  J Clin Oncol       Date:  2019-09-18       Impact factor: 44.544

Review 5.  Genomic correlates of response to immune checkpoint blockade.

Authors:  Tanya E Keenan; Kelly P Burke; Eliezer M Van Allen
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

Review 6.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

7.  Management of NK/T-Cell Lymphoma, Nasal Type.

Authors:  Pamela B Allen; Mary Jo Lechowicz
Journal:  J Oncol Pract       Date:  2019-10       Impact factor: 3.840

8.  Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT.

Authors:  Nobuaki Nakano; Atae Utsunomiya; Keitaro Matsuo; Noriaki Yoshida; Masao Seto; Kouichi Ohshima; Hiroshi Fujiwara; Shigeo Fuji; Yoshifusa Takatsuka; Ayumu Ito; Toshihiro Miyamoto; Youko Suehiro; Hirohisa Nakamae; Yasushi Sawayama; Mitsuhiro Yuasa; Yasuhiko Miyazaki; Shuichi Ota; Kazunori Imada; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Koji Kato
Journal:  Blood Adv       Date:  2021-01-26

Review 9.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151

Review 10.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.